The development of a technology-based information support intervention (iSupport) among patients with differentiated thyroid cancer post radioactive iodine therapy

针对放射性碘治疗后分化型甲状腺癌患者开发基于技术的信息支持干预 (iSupport)

• 批准号: 10581121
• 负责人: Alaina L Carr
• 金额: $ 13.1万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-02 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10581121
• 关键词: Address; Adverse effects; Aftercare; Appointment; Behavior Therapy; Behavioral; Behavioral Model; Cancer Control; Cancer Patient; Caring; Cellular Phone; Clinical; Clinical Trials Design; Computers; Control Groups; Coping Skills; Data; Development; Devices; Diagnosis; Distress; Education; Educational Intervention; Eligibility Determination; Endocrine; Enrollment; European Organization for Research and Treatment of Cancer; Evidence based intervention; Feedback; Focus Groups; Follicular thyroid carcinoma; Frequencies; Frustration; Functional disorder; Future; Goals; Gold; Grant; Individual; Information Management; Intervention; Interview; Knowledge; Lacrimal gland structure; Late Effects; Leadership; Malignant Neoplasms; Malignant neoplasm of thyroid; Measures; Mentors; Mentorship; Nose; Online Systems; Oral health; Pain; Papillary Carcinoma; Participant; Patient Selection; Patient-Focused Outcomes; Patients; Persons; Phase; Population; Prognosis; Provider; Radioactive Iodine; Randomized; Randomized, Controlled Trials; Recommendation; Reporting; Research; Research Design; Research Personnel; Salivary; Salivary Glands; Second Primary Cancers; Self Efficacy; Sleep; Social Functioning; Stress; Survival Rate; Symptoms; System; Technology; Testing; Training; Treatment Efficacy; Treatment Side Effects; Writing; acceptability and feasibility; alternative treatment; cancer therapy; cancer type; career development; common symptom; coping; design; digital health; digital technology; empowerment; experience; follow-up; health related quality of life; improved; intervention effect; lacrimal; novel; oral mucositis; patient population; pilot test; primary outcome; radioiodine therapy; reduce symptoms; secondary outcome; side effect; skills; social cognitive theory; support tools; survival outcome; survivorship; symptom management; symptom treatment; therapy design; therapy development; tool; treatment as usual; treatment comparison; treatment effect; understudied cancer; usability; web-based intervention

Abstract Radioactive iodine (RAI) therapy is routinely used among patients diagnosed with differentiated thyroid cancer (DTC), with approximately 76% of patients receiving RAI. Patients with DTC post RAI treatment report extensive short-term and late effects of treatment, symptom burden, and unmet informational needs about treatment related side effects. However, thyroid cancer is frequently referred to as the “good cancer” and is an understudied cancer population for survivorship research and web-based interventions. One way to address these gaps is through digital technologies such as a web-based intervention, which can empower patients with direct access to educational and support tools to reduce symptom burden. I propose to develop and evaluate a web-based intervention, called iSupport (informational support among patients post RAI treatment), to reduce symptom burden among patients diagnosed with DTC post RAI. I propose the following aims: Aim 1 (K99). Develop iSupport, a web-based intervention, for patients with DTC post RAI therapy. Aim 2 (K99). Test the usability of the newly developed iSupport intervention among patients with DTC post RAI. Aim 3 (R00). Assess the feasibility and acceptability of the iSupport intervention. Aim 4 (R00). Test the preliminary efficacy of the iSupport intervention vs. treatment as usual (TAU) among patients with DTC on symptom burden. The K99 phase will involve: 1) conducting patient focus groups (N=32) and individual stakeholder interviews (N=12) to develop iSupport and 2) testing the usability of the iSupport intervention among patients with DTC post RAI therapy (N=8). The R00 phase will involve conducting a pilot randomized controlled trial (RCT; N=72) to: 1) assess the feasibility and acceptability of iSupport and 2) test the preliminary efficacy of iSupport compared to a (TAU) control group with DTC patients on RAI-related symptom burden, patient bioheath indicators (oral mucositis; oral health problems), knowledge of DTC and RAI, self-efficacy for coping with side effects, cancer- related distress, and health-related quality of life. The overall objective of the K99/R00 is to provide Dr. Carr with training and mentorship to become an independent cancer control investigator with expertise in digital technology evidenced-based interventions among cancer patients. The K99 training goals include: 1) increase knowledge of clinical concerns and symptoms among patients with DTC post RAI, 2) obtain advanced training in technology-based intervention design and development, 3) develop expertise in behavioral intervention clinical trials design and testing, and 4) refine grant writing and leadership skills for future independence. Dr. Carr’s mentorship team includes Drs. Kristi Graves (primary), Jacqueline Jonklaas (co-mentor), and Kristen Miller (co-mentor) who are committed to her career development. The proposed training plan will facilitate Dr. Carr’s transition to independence as a cancer control researcher with expertise in digital health interventions to reduce symptom burden and improve health-related quality of life in cancer patient outcomes after treatment.

抽象的 放射性碘（RAI）疗法通常在被诊断为分化甲状腺癌的患者中使用 （DTC），大约有76％的患者接受RAI。 DTC后RAI治疗报告患者 有关治疗，症状伯恩（Burnen）症状以及未满足的信息需求的广泛的短期和晚期影响 治疗相关的副作用。但是，甲状腺癌经常被称为“好癌症”，是 研究了生存研究和基于网络的干预措施的癌症人群。一种解决方法 这些差距是通过基于Web的干预等数字技术来赋予患者的能力的数字技术。 直接获取教育和支持工具，以减少症状伯恩。我建议开发和评估 基于Web的干预措施，称为Isupport（RAI治疗后患者之间的信息支持），以减少 被诊断为DTC后RAI的患者的症状燃烧。我提出以下目的：目标1（K99）。 为DTC后RAI治疗患者开发ISUPPORT，这是一种基于Web的干预措施。目标2（K99）。测试 DTC后RAI患者中新开发的ISUPPORT干预的可用性。目标3（R00）。 评估Isupport干预的可行性和可接受性。目标4（R00）。测试初步效率 在症状伯嫩患有DTC的患者中，Isupport干预与往常一样（TAU）。这 K99阶段将涉及：1）进行患者焦点小组（n = 32）和单个利益相关者访谈（n = 12） 开发Isupport和2）在RAI后DTC患者中测试Isupport干预的可用性 治疗（n = 8）。 R00阶段将涉及进行试验随机对照试验（RCT； n = 72）至：1） 评估Isupport的可行性和可接受性，2）与Isupport相比的初步效率测试 A（TAU）对照组与DTC患者有关RAI相关症状Burnen，患者Bioheath指标（口服） 粘膜炎；口腔健康问题），DTC和RAI知识，应对副作用的自我效应，癌症 - 相关的困扰和与健康相关的生活质量。 K99/R00的总体目标是为Carr博士提供 培训和心态成为数字专家的独立癌症控制调查员 技术证明了癌症患者的干预措施。 K99培训目标包括：1）增加 DTC后RAI患者中临床问题和症状的了解，2）获得高级培训 在基于技术的干预设计和开发中，3）发展行为干预方面的专业知识 临床试验设计和测试，以及4）完善赠款写作和领导能力，以实现未来的独立性。博士 Carr的Mentalship团队包括Drs。克里斯蒂·格雷夫斯（Kristi Graves）（小学），杰奎琳·乔克拉斯（Jacqueline Jonklaas）（联合国）和克里斯汀（Kristen） 米勒（Co-Insor）致力于自己的职业发展。拟议的培训计划将有助于博士。 卡尔（Carr 减少症状伯嫩并改善治疗后癌症患者结局的健康相关生活质量。